Biogen Inc. - Company & Market Research Reports

Home /
Companies /
Biogen Inc.

Founded in 1978 Biogen Inc is a global biotechnology company with its headquarters in Cambridge, Massachusetts. In 2003 Biogen merged with Idec Pharmaceuticals to create Biogen Idec and acquired Syntonix Pharmaceuticals in 2007. In 2015 the company returned to its original name Biogen Inc and acquired Convergence Pharmaceuticals. Biogen focuses on drug discovery for a range of conditions including neuropathic pain, hemophilia, organ failure, neuromuscular disorders and oncology. Their product portfolio includes Rituxan, Avonex, Tecfidera and Eloctate.

REFINE BY

KEYWORD

CATEGORIES

Central Nervous System Drugs 148
Immune Disorders Drugs 79
Genomics 79
Biopharmaceuticals 79
Drug Discovery 66
Oncology Drugs 53
Biotechnology 49
Pharmaceuticals 43
Musculoskeletal Disorders Drugs 41
Hematological Drugs 38
Biosimilars and Biosuperiors 30
Cardiovascular Drugs 26
Clinical Trials 26
Alzheimer's Disease Drugs 26
Allergy and Immunology 20
Infusions and Injectables 20
Optical Disorders Drugs 19
Infectious Diseases Drugs 19
Respiratory Drugs 18
Mental Disorders Drugs 18
Gastrointestinal Drugs 17
Needles and Syringes 16
E-Healthcare 14
Psoriasis Drugs 14
Pharmaceutical Manufacturing 14
Immunosuppressive Drugs 14
Neurology 13
Healthcare Services 13
Hematology 13
Drug Delivery 12
Endocrine and Metabolic Disorders Drugs 12
Lymphoma Drugs 11
Analgesics 10
Leukemia Drugs 9
Optical 9
Diagnostics 9
Liver and Kidney Disorders Drugs 9
Therapeutic Area 8
Drugs by Therapeutic Area 7
Pulmonary Medicine 7
Medical Devices 7
Company Reports 6
Enzymes 6
Hospital Management 5
Cardiology 5
Oncology 5
Proteomics 4
Neurology Devices 4
Vaccines 4
Dermatological Drugs 4
Schizophrenia Drugs 4
Pharmaceutical Intermediates 3
Generic Drugs 3
Pharmacoeconomics 3
Lung Cancer Drugs 3
Diabetes Devices 3
Stem Cells 3
Biomaterials 3
Mental Health 3
Vitamins and Dietary Supplements 3
Laboratory Equipment 3
Gastroenterology 3
In Vitro Diagnostics 2
Managed Care 2
Dermatology 2
Skin Cancer Drugs 2
Nanomedicine 2
Anxiety Drugs 2
Asthma Drugs 2
Urology and Nephrology 1
Women's Health 1
Fertility Services 1
Breast Cancer Drugs 1
Prostate Cancer Drugs 1
Colon Cancer Drugs 1
Cervical Cancer Drugs 1
Medical Imaging 1
Orthopedic Devices 1
Infectious Disease Testing 1
Computed Tomography 1
Transdermal and Transmucosal Drug Delivery 1
Biomarkers 1
Surgical Procedures 1
Contrast Media 1
Kidney Cancer Drugs 1
Antibiotics 1
Clinical Skills 1
Pediatrics 1
Anatomy 1
Allergy Drugs 1
Sexual and Reproductive Health Drugs 1

SHOW ALL

REPORT TYPE

All Reports

Company Reports

Market Reports

Google Reviews

4.8



276 reviews

913 Results (Page 20 of 46)
- Relevance
  Sort by

South Africa Biopharmaceuticals Market - Industry Outlook & Forecast 2023-2028

 Report
August 2023
202 Pages
South Africa

From

€3477EUR$3,500USD£2,891GBP

Hematological Disorders Diagnostic And Therapeutic Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type

 Report
February 2022
95 Pages
Global

From

€3200EUR$3,451USD£2,754GBP

Oncology Biosimilars Global Market Report 2024

 Report
February 2024
250 Pages
Global

From

€4967EUR$5,000USD£4,130GBP

Biosimilar Hormones Global Market Report 2024

 Report
February 2024
250 Pages
Global

From

€4967EUR$5,000USD£4,130GBP

Biosimilar Interleukins Global Market Report 2024

 Report
February 2024
250 Pages
Global

From

€4967EUR$5,000USD£4,130GBP

NEED HELP FINDING THE RIGHT PRODUCT? Farid will help you find what you are looking for.

Call: 1-800-526-8630 ASK A QUESTION REQUEST A CALL BACK

Biosimilar Lymphocyte Modulator Global Market Report 2024

 Report
February 2024
250 Pages
Global

From

€4967EUR$5,000USD£4,130GBP

Biosimilars Global Market Report 2024

 Report
February 2024
250 Pages
Global

From

€4967EUR$5,000USD£4,130GBP

Biologic & Biosimilar RA Drugs Global Market Report 2024

 Report
January 2024
200 Pages
Global

From

€4967EUR$5,000USD£4,130GBP

Schistosomiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

 Report
June 2022
40 Pages
Global

From

€1987EUR$2,000USD£1,652GBP

Hemophilia Drugs - Global Strategic Business Report

 Report
November 2024
182 Pages
Global

From

€4918EUR$4,950USD£4,089GBP

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

 Report
April 2022
138 Pages
Global

From

€3477EUR$3,500USD£2,891GBP

Lung Cancer Drugs Global Market Report 2024

 Report
November 2023
175 Pages
Global

From

€4967EUR$5,000USD£4,130GBP

Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

 Report
September 2022
672 Pages
Global

From

€2484EUR$2,500USD£2,065GBP

Parkinson's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

 Report
September 2022
1079 Pages
Global

From

€2484EUR$2,500USD£2,065GBP

Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

 Report
September 2022
269 Pages
Global

From

€1987EUR$2,000USD£1,652GBP

Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

 Report
November 2022
370 Pages
Global

From

€4917EUR$5,123USD£3,950GBP

Oral Proteins and Peptides Market by Target Disease Indication, Type of Molecule, Technology Platforms, Biological Target, Mechanism of Action, Key Players, and Key Geographical Regions, 2022-2032

 Report
February 2022
421 Pages
Global

From

€4768EUR$4,799USD£3,964GBP

Marburgvirus Infections (Marburg Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

 Report
May 2022
99 Pages
Global

From

€1987EUR$2,000USD£1,652GBP

Lassa Fever (Lassa Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

 Report
May 2022
65 Pages
Global

From

€1987EUR$2,000USD£1,652GBP

Cognitive Impairment Associated with Schizophrenia-CIAS - Pipeline Insight, 2024

 Clinical Trials
April 2024
60 Pages
Global

From

€869EUR$875USD£723GBP

€1242EUR$1,250USD£1,032GBP

913 Results (Page 20 of 46)
- 1
- 18
- 19
- 20
- 21
- 22

ASK A QUESTION

An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net

*Required Information

Name*

Email Address* Please provide your business or academic email address.

Country*

Phone Number*

Your Question*

I have read Research and Markets' Privacy Policy and consent to the processing of my personal data.

We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.